Is the Reason why BioLineRx Ltd. (NASDAQ: BLRX) stock was hitting the roof early in the Morning

BioLineRx Ltd. (NASDAQ: BLRX) stock is up nearly 28 percent to hit $4.3 in pre-market trading, considering the Bio-tech company’s lack of reports or news releases. And what do you want to discover? And why is today’s BLRX stock trending higher? Here’s the latest update for investors to learn about BioLineRx Ltd (NASDAQ: BLRX).

 An oncology-focused, late clinical-stage biotech firm officially posted and offered a corporate overview of its financial performance for the quarter ended September 30, 2020.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The company posted positive findings from a pre-planned interim review of the GENESIS Phase 3 stem cell mobilization motixafortide trial in multiple myeloma patients have been published. The Data Management Committee considered statistically relevant evidence supporting primary endpoint care of motixafortide and eventually released a recommendation to halt patient registration promptly. The research registration of 122 patients was performed according to the DMC guideline (instead of 177 as originally planned). SCM is the most successful registration route for the Company;

BLRX also reported initiation of the investigator-initiated Phase 2 analysis of motixafortide in conjunction with LIBTAYO and first-line PDAC chemotherapy. Columbia University is conducting the research;

Moreover, it reported initiation of a Phase 1b investigator-initiated analysis to test motixafortide in patients hospitalized with acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections, performed by Wolfson Medical Center in Holon, Israel;

Most Popular

Related posts